BridgeBio Pharma, Inc. Impairment of Long-Lived Assets Held-for-use
BridgeBio Pharma, Inc. (BBIO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-02-24
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $0.00.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $271.00K.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BridgeBio Pharma, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $12.72M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $271.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $271.00K 10-Q · filed 2025-10-29 | $271.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $271.00K 10-Q · filed 2025-08-05 | $271.00K derived: sum of 3 quarters · filed 2026-02-24 | $271.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $271.00K 10-Q · filed 2025-04-29 | $271.00K derived: sum of 2 quarters · filed 2026-02-24 | $271.00K derived: sum of 3 quarters · filed 2026-02-24 | $271.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $67.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $67.00K derived: sum of 3 quarters · filed 2025-02-20 | $67.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $67.00K derived: sum of 2 quarters · filed 2025-02-20 | $67.00K derived: sum of 3 quarters · filed 2025-02-20 | $12.72M 10-K · filed 2025-02-20 |
| 2022-09-30 | $67.00K 10-Q · filed 2023-11-02 | $67.00K derived: sum of 2 quarters · filed 2023-11-02 | $12.72M 10-Q · filed 2023-11-02 | $9.42M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $12.65M 10-Q · filed 2023-08-03 | $9.35M derived: sum of 3 quarters · filed 2024-02-22 | $9.35M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $12.65M 10-Q · filed 2023-05-04 | $9.35M derived: sum of 2 quarters · filed 2024-02-22 | $9.35M derived: sum of 3 quarters · filed 2024-02-22 | $9.35M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$3.30M derived: sum of 2 quarters · filed 2024-02-22 | -$3.30M derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $3.30M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.30M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $3.30M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |